Table of Contents
BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC plans to acquire four generic drug products from Actavis Inc.
Terms of the cash deal weren’t disclosed. Amneal said Monday that the transaction is slated to be completed after the closing of Actavis’ acquisition of Warner Chilcott, which those companies’ shareholders approved earlier this month.
The four products being purchased by Amneal are generic versions of Warner Chilcott medications.
One of those generics is currently marketed in the United States by Actavis: Zenchent Fe (norethindrone acetate/ethinyl estradiol), the generic version of Warner Chilcott’s Femcon Fe. Amneal said it expects to start shipping Zenchent Fe, an oral contraceptive, immediately after the acquisition is finalized.
Two of the products Amneal is buying have Abbreviated New Drug Applications (ANDAs) awaiting regulatory approval: norethindrone acetate/ethinyl estradiol, the generic version of Warner Chilcott’s birth control pill Lo Loestrin Fe, and risedronate sodium, the generic version of Warner Chilcott’s Atelvia, indicated for the treatment of osteoporosis in women after menopause.
Amneal said the other product it’s acquiring — norethindrone acetate/ethinyl estradiol, the generic equivalent of Warner Chilcott’s oral contraceptive Loestrin 24 Fe — has been approved but isn’t currently marketed, based on a settlement agreement.
Actavis has reported that it expects the acquisition of Warner Chilcott to close early in the fourth quarter of this year.
